AI Article Synopsis
- Experiments used Phenotype Mammalian Microarray (PM-M) technology to analyze lymphoblastoid cell lines from individuals with autism spectrum disorder (ASD) and age-matched controls.
- The study focused on optimizing parameters like sample size and incubation time to effectively measure the utilization of the amino acid tryptophan while minimizing errors.
- Results indicated significant differences in NADH production related to tryptophan compounds between ASD individuals and control samples.
Article Abstract
Experiments employing the Phenotype Mammalian Microarray (PM-M) technology were performed on lymphoblastoid cell lines (LCLs) from individuals with autism spectrum disorder (ASD) and age-matched controls. We used the custom-made PM-M plate designed to assess differential utilization of the amino acid tryptophan. Multiple parameters such as the sample size, incubation time, and cell concentration have been tested, leading to optimized protocols and minimized background noise by variable selection while controlling for false discoveries. The assay generated data based on the production of nicotinamide adenine dinucleotide (NADH) in the presence of different compounds containing tryptophan and showed clear differences between ASD and control samples.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8633810 | PMC |
| http://dx.doi.org/10.1016/j.dib.2021.107598 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!